AstraZeneca stroke trials show Brilinta not effective
23rd Mar 2016 07:10
(ShareCast News) - AstraZeneca's Brilinta drug missed its target during a trial in stroke patients, proving less effective than aspirin. Clinical tests of Brilinta had been assessing efficacy of 90mg tablets taken twice daily compared to aspirin 100mg once daily in patients with acute ischaemic stro
Read moreTuesday broker round-up
15th Mar 2016 16:46
(ShareCast News) - Virgin Money: Goldman Sachs reiterates neutral with a target price of 450p and Berenberg stays at hold with a 400p target. Gem Diamonds: Panmure Gordon keeps at buy, 181p target and Finncap reiterates buy with a target of 270p. G4S: Credit Suisse reiterates neutral with a target
Read moreFTSE 100 movers: Miners gain but HSBC slumps on Bernstein note
29th Feb 2016 13:47
(ShareCast News) - London's FTSE 100 index was down 0.3% to 6,075.39 at 1525 GMT, as investors weighed up disappointment that the G20 meeting did not yield a coordinated stimulus effort against the People's Bank of China's move to cut the reserve requirement ratio. HSBC was in the red after Bernstei
Read moreAstraZeneca signs China licensing deal for Plendil
29th Feb 2016 08:27
(ShareCast News) - AstraZeneca has entered a licensing deal with China Medical System Holdings Ltd for the commercialisation rights in China to its hypertension medicine Plendil. Under the terms of the agreement, which does not include the transfer of any AstraZeneca employees or facilities, China M
Read moreSunday newspaper round-up: Pound, GSK, Sainsbury's, HSBC
28th Feb 2016 17:29
(ShareCast News) - Sterling will fall to $1.28 by the end of 2016, its lowest level against the US dollar in three decades, currency strategists have cautioned. If Britain votes to leave the European Union the fall will be even worse, the Sunday Telegraph reported that Deutsche Bank analysts saw a f
Read moreAstraZeneca buoyed by Oprhan recommendations for Acerta cancer drug
25th Feb 2016 08:59
(ShareCast News) - AstraZeneca has been buoyed by news that its acalabrutinib cancer treatment has been recommended for orphan drug status by the European Medicines Agency (EMA) for three forms of lymphoma. The EMA gave positive opinions for the acalabrutinib in the treatment of chronic lymphocytic
Read moreAstraZeneca gets European approval for Zurampic and Brilique
19th Feb 2016 07:14
(ShareCast News) - The European Commission has given AstraZeneca's Zurampic drug marketing authorisation for the treatment of gout in the European Union. It has been approved in combination with a xanthine oxidase inhibitor (XOI) to treat hyperuricemia in adult gout patients who have not achieved ta
Read moreLondon pre-open: Stocks seen higher as investors eye UK data, FOMC minutes
17th Feb 2016 07:16
(ShareCast News) - London stocks are expected to open higher on Wednesday following a positive close in the US, as investors look to a slew of UK data releases and the latest FOMC minutes. London's FTSE 100 is seen starting 15 points higher than Tuesday's close at 5,877. On the data front, the UK u
Read moreAstrazeneca wins fast-track approval for bladder cancer drug
17th Feb 2016 07:09
(ShareCast News) - AstraZeneca has won fast-track US regulatory approval for a particular application of its most promising cancer drugs. Durvalumab, a highly innovative immuno-oncology treatment that helps empower the patient's immune system and attack the cancer, has been given Breakthrough Therap
Read moreBroker tips: Wood Group, ITV, AstraZeneca
8th Feb 2016 15:55
(ShareCast News) - Wood Group shares fell after Goldman Sachs downgraded the company from 'neutral' to 'sell' and cut its target price from 639.6p to 517.6p. In a note on Monday, the investment bank focused on working capital analysis, which it believed would be the key there for the oil services se
Read moreMonday broker round-up
8th Feb 2016 15:02
(ShareCast News) - Petrofac: Goldman Sachs downgrades to neutral with a target of 909.8p. G4S: Jefferies downgrades to underperform with a target price of 170p. Cairn Energy: RBC keeps at outperform, 200p target. Wood Group: Goldman Sachs downgrades to sell, 517.6p target. Amec Foster Wheeler: No
Read moreHSBC downgrades AstraZeneca, sees no near-term relief
8th Feb 2016 12:18
(ShareCast News) - HSBC downgraded AstraZeneca to 'hold' from 'buy' and cut the price target to 4,880p from 4,910p. It said the company's full year results last Thursday were solid, slightly ahead of expectations in terms of sales and in line at core earnings per share level. The bank said declines
Read moreFriday broker round-up
5th Feb 2016 15:07
(ShareCast News) - Enterprise Inns: Barclays downgrades to underweight with a target of 80p. Thomas Cook: HSBC reiterates hold with a target price of 100p and JP Morgan keeps at overweight with a 170p target. Victrex: Deutsche Bank keeps at hold, 2000p target, UBS maintains neutral with a target
Read moreFriday newspaper share tips: AstraZeneca at least worth holding on to
5th Feb 2016 10:44
(ShareCast News) - AstraZeneca was in focus in Friday's newspaper share tips after it warned 2016 profits could be hit with the expiry of the patent on its anti-cholesterol drug Crestor. The FTSE 100 company said it sees a low to mid single-digit percentage decline in both sales and profits in 2016
Read moreThursday broker round-up
4th Feb 2016 16:07
(ShareCast News) - Coca-Cola HBC: Barclays downgrades to underweight with a target of 1325p. TalkTalk: Goldman Sachs downgrades to neutral with a target of 271p. Paragon Group: JP Morgan downgrades to neutral and sets a 380p target. Antofagasta: Investec reiterates sell with a target of 305p. Ang
Read more